• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2022

    6/17/22 11:10:46 AM ET
    $ACHC
    $AEO
    $APG
    $AXP
    Medical Specialities
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Get the next $ACHC alert in real time by email

    Upgrades

    TD Securities upgraded the previous rating for AT&T Inc (NYSE:T) from Hold to Buy. In the first quarter, AT&T showed an EPS of $0.77, compared to $0.86 from the year-ago quarter. The stock has a 52-week-high of $29.35 and a 52-week-low of $18.67. At the end of the last trading period, AT&T closed at $18.96.

    B of A Securities upgraded the previous rating for The AZEK Co Inc (NYSE:AZEK) from Neutral to Buy. AZEK Co earned $0.33 in the second quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $46.56 and a 52-week-low of $15.52. At the end of the last trading period, AZEK Co closed at $15.79.

    Baird upgraded the previous rating for M&T Bank Corp (NYSE:MTB) from Neutral to Outperform. For the first quarter, M&T Bank had an EPS of $2.73, compared to year-ago quarter EPS of $3.41. At the moment, the stock has a 52-week-high of $186.95 and a 52-week-low of $128.46. M&T Bank closed at $160.64 at the end of the last trading period.

    For Fifth Third Bancorp (NASDAQ:FITB), Baird upgraded the previous rating of Neutral to Outperform. In the first quarter, Fifth Third Bancorp showed an EPS of $0.68, compared to $0.93 from the year-ago quarter. The current stock performance of Fifth Third Bancorp shows a 52-week-high of $50.64 and a 52-week-low of $33.00. Moreover, at the end of the last trading period, the closing price was at $33.25.

    According to Baird, the prior rating for Capital One Financial Corp (NYSE:COF) was changed from Neutral to Outperform. In the first quarter, Capital One Financial showed an EPS of $5.62, compared to $7.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $177.95 and a 52-week-low of $98.54. Capital One Financial closed at $102.11 at the end of the last trading period.

    According to Baird, the prior rating for American Express Co (NYSE:AXP) was changed from Neutral to Outperform. In the first quarter, American Express showed an EPS of $2.73, compared to $2.74 from the year-ago quarter. The stock has a 52-week-high of $199.55 and a 52-week-low of $136.49. At the end of the last trading period, American Express closed at $137.50.

    Goldman Sachs upgraded the previous rating for Utz Brands Inc (NYSE:UTZ) from Neutral to Buy. Utz Brands earned $0.11 in the first quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.92 and a 52-week-low of $12.06. Utz Brands closed at $12.34 at the end of the last trading period.

    For NextEra Energy Partners LP (NYSE:NEP), RBC Capital upgraded the previous rating of Sector Perform to Outperform. For the first quarter, NextEra Energy Partners had an EPS of $1.72, compared to year-ago quarter EPS of $2.66. The stock has a 52-week-high of $88.80 and a 52-week-low of $61.31. At the end of the last trading period, NextEra Energy Partners closed at $67.20.

    According to JP Morgan, the prior rating for ZIM Integrated Shipping Services Ltd (NYSE:ZIM) was changed from Underweight to Neutral. In the first quarter, ZIM Integrated Shipping showed an EPS of $14.19, compared to $5.13 from the year-ago quarter. The stock has a 52-week-high of $91.23 and a 52-week-low of $33.71. At the end of the last trading period, ZIM Integrated Shipping closed at $48.80.

    See all analyst ratings upgrades.

    Downgrades

    According to Wells Fargo, the prior rating for Toll Brothers Inc (NYSE:TOL) was changed from Overweight to Equal-Weight. In the second quarter, Toll Brothers showed an EPS of $1.85, compared to $1.01 from the year-ago quarter. At the moment, the stock has a 52-week-high of $75.61 and a 52-week-low of $40.88. Toll Brothers closed at $41.58 at the end of the last trading period.

    For Olin Corp (NYSE:OLN), Citigroup downgraded the previous rating of Buy to Neutral. For the first quarter, Olin had an EPS of $2.48, compared to year-ago quarter EPS of $1.54. The stock has a 52-week-high of $67.25 and a 52-week-low of $39.90. At the end of the last trading period, Olin closed at $49.29.

    B of A Securities downgraded the previous rating for Dream Finders Homes Inc (NASDAQ:DFH) from Neutral to Underperform. For the first quarter, Dream Finders Homes had an EPS of $0.42, compared to year-ago quarter EPS of $0.18. The current stock performance of Dream Finders Homes shows a 52-week-high of $25.42 and a 52-week-low of $11.50. Moreover, at the end of the last trading period, the closing price was at $11.82.

    For Owens-Corning Inc (NYSE:OC), B of A Securities downgraded the previous rating of Buy to Underperform. Owens-Corning earned $2.84 in the first quarter, compared to $1.73 in the year-ago quarter. The stock has a 52-week-high of $101.12 and a 52-week-low of $75.58. At the end of the last trading period, Owens-Corning closed at $76.19.

    According to Truist Securities, the prior rating for Roblox Corp (NYSE:RBLX) was changed from Buy to Hold. Roblox earned $0.27 in the first quarter, compared to $0.46 in the year-ago quarter. The stock has a 52-week-high of $141.60 and a 52-week-low of $21.65. At the end of the last trading period, Roblox closed at $24.69.

    Citigroup downgraded the previous rating for Dow Inc (NYSE:DOW) from Buy to Neutral. For the first quarter, Dow had an EPS of $2.34, compared to year-ago quarter EPS of $1.36. At the moment, the stock has a 52-week-high of $71.86 and a 52-week-low of $52.07. Dow closed at $55.42 at the end of the last trading period.

    Citigroup downgraded the previous rating for Westlake Corp (NYSE:WLK) from Buy to Neutral. For the first quarter, Westlake had an EPS of $5.83, compared to year-ago quarter EPS of $1.87. At the moment, the stock has a 52-week-high of $141.19 and a 52-week-low of $78.06. Westlake closed at $100.91 at the end of the last trading period.

    Citigroup downgraded the previous rating for CF Industries Holdings Inc (NYSE:CF) from Buy to Neutral. CF Industries Holdings earned $4.21 in the first quarter, compared to $0.70 in the year-ago quarter. At the moment, the stock has a 52-week-high of $113.48 and a 52-week-low of $43.19. CF Industries Holdings closed at $90.61 at the end of the last trading period.

    According to Raymond James, the prior rating for PROG Holdings Inc (NYSE:PRG) was changed from Outperform to Market Perform. In the first quarter, PROG Holdings showed an EPS of $0.57, compared to $1.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of $52.06 and a 52-week-low of $16.22. PROG Holdings closed at $16.57 at the end of the last trading period.

    According to B. Riley Securities, the prior rating for Urban Outfitters Inc (NASDAQ:URBN) was changed from Buy to Neutral. Urban Outfitters earned $0.33 in the first quarter, compared to $0.54 in the year-ago quarter. The stock has a 52-week-high of $42.10 and a 52-week-low of $17.81. At the end of the last trading period, Urban Outfitters closed at $20.34.

    Wells Fargo downgraded the previous rating for M.D.C. Holdings Inc (NYSE:MDC) from Equal-Weight to Underweight. M.D.C. Holdings earned $2.02 in the first quarter, compared to $1.51 in the year-ago quarter. At the moment, the stock has a 52-week-high of $56.53 and a 52-week-low of $29.03. M.D.C. Holdings closed at $29.64 at the end of the last trading period.

    For Meritage Homes Corp (NYSE:MTH), Wells Fargo downgraded the previous rating of Equal-Weight to Underweight. Meritage Homes earned $5.79 in the first quarter, compared to $3.44 in the year-ago quarter. At the moment, the stock has a 52-week-high of $125.01 and a 52-week-low of $66.08. Meritage Homes closed at $66.82 at the end of the last trading period.

    B. Riley Securities downgraded the previous rating for American Eagle Outfitters Inc (NYSE:AEO) from Buy to Neutral. In the first quarter, American Eagle Outfitters showed an EPS of $0.16, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $38.99 and a 52-week-low of $11.43. At the end of the last trading period, American Eagle Outfitters closed at $11.86.

    See all analyst ratings downgrades.

    Initiations

    Loop Capital initiated coverage on Acadia Healthcare Co Inc (NASDAQ:ACHC) with a Hold rating. In the first quarter, Acadia Healthcare Co showed an EPS of $0.67, compared to $0.47 from the year-ago quarter. The current stock performance of Acadia Healthcare Co shows a 52-week-high of $76.69 and a 52-week-low of $50.07. Moreover, at the end of the last trading period, the closing price was at $66.15.

    Loop Capital initiated coverage on HCA Healthcare Inc (NYSE:HCA) with a Buy rating. The price target for HCA Healthcare is set to $240.00. For the first quarter, HCA Healthcare had an EPS of $4.12, compared to year-ago quarter EPS of $4.14. At the moment, the stock has a 52-week-high of $279.02 and a 52-week-low of $169.12. HCA Healthcare closed at $171.56 at the end of the last trading period.

    Cowen & Co. initiated coverage on Starry Group Holdings Inc (NYSE:STRY) with an Outperform rating. The price target for Starry Group Holdings is set to $9.00. The current stock performance of Starry Group Holdings shows a 52-week-high of $10.90 and a 52-week-low of $4.03. Moreover, at the end of the last trading period, the closing price was at $4.11.

    Maxim Group initiated coverage on Femasys Inc (NASDAQ:FEMY) with a Buy rating. The price target for Femasys is set to $5.00. Femasys earned $0.24 in the first quarter, compared to $1.84 in the year-ago quarter. The stock has a 52-week-high of $13.75 and a 52-week-low of $1.26. At the end of the last trading period, Femasys closed at $1.30.

    Morgan Stanley initiated coverage on Cvent Holding Corp (NASDAQ:CVT) with a Equal-Weight rating. The price target for Cvent Holding is set to $5.50. Cvent Holding earned $0.07 in the first quarter, compared to $0.04 in the year-ago quarter. The stock has a 52-week-high of $10.96 and a 52-week-low of $3.30. At the end of the last trading period, Cvent Holding closed at $4.79.

    Raymond James initiated coverage on CTO Realty Growth Inc (NYSE:CTO) with an Outperform rating. The price target for CTO Realty Growth is set to $69.00. In the first quarter, CTO Realty Growth showed an EPS of $1.48, compared to $0.97 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.38 and a 52-week-low of $51.98. CTO Realty Growth closed at $57.69 at the end of the last trading period.

    B. Riley Securities initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT) with a Buy rating. The price target for ChargePoint Hldgs is set to $20.00. For the first quarter, ChargePoint Hldgs had an EPS of $0.21, compared to year-ago quarter EPS of $0.17. At the moment, the stock has a 52-week-high of $36.86 and a 52-week-low of $8.50. ChargePoint Hldgs closed at $12.55 at the end of the last trading period.

    With an Outperform rating, BMO Capital initiated coverage on Legend Biotech Corp (NASDAQ:LEGN). The price target seems to have been set at $77.00 for Legend Biotech. For the first quarter, Legend Biotech had an EPS of $0.24, compared to year-ago quarter EPS of $0.30. At the moment, the stock has a 52-week-high of $58.00 and a 52-week-low of $30.75. Legend Biotech closed at $42.96 at the end of the last trading period.

    With an Overweight rating, Barclays initiated coverage on Archaea Energy Inc (NYSE:LFG). The price target seems to have been set at $26.00 for Archaea Energy. The current stock performance of Archaea Energy shows a 52-week-high of $23.75 and a 52-week-low of $14.30. Moreover, at the end of the last trading period, the closing price was at $18.56.

    With a Buy rating, Deutsche Bank initiated coverage on Grab Holdings Inc (NASDAQ:GRAB). The price target seems to have been set at $3.20 for Grab Hldgs. The current stock performance of Grab Hldgs shows a 52-week-high of $13.29 and a 52-week-low of $2.26. Moreover, at the end of the last trading period, the closing price was at $2.35.

    With a Buy rating, B. Riley Securities initiated coverage on Tritium DCFC Ltd (NASDAQ:DCFC). The price target seems to have been set at $12.00 for Tritium DCFC. The stock has a 52-week-high of $19.75 and a 52-week-low of $5.72. At the end of the last trading period, Tritium DCFC closed at $5.77.

    B. Riley Securities initiated coverage on Beam Global (NASDAQ:BEEM) with a Buy rating. The price target for Beam Glb is set to $23.00. In the first quarter, Beam Glb showed an EPS of $0.24, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $41.05 and a 52-week-low of $10.19. Beam Glb closed at $13.60 at the end of the last trading period.

    With a Neutral rating, B. Riley Securities initiated coverage on Blink Charging Co (NASDAQ:BLNK). The price target seems to have been set at $15.00 for Blink Charging. Blink Charging earned $0.36 in the first quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $49.00 and a 52-week-low of $13.60. Blink Charging closed at $14.46 at the end of the last trading period.

    BMO Capital initiated coverage on Verve Therapeutics Inc (NASDAQ:VERV) with an Outperform rating. The price target for Verve Therapeutics is set to $48.00. In the first quarter, Verve Therapeutics showed an EPS of $0.62, compared to $4.99 from the year-ago quarter. At the moment, the stock has a 52-week-high of $78.00 and a 52-week-low of $10.70. Verve Therapeutics closed at $11.14 at the end of the last trading period.

    With an Outperform rating, BMO Capital initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP). The price target seems to have been set at $98.00 for CRISPR Therapeutics. CRISPR Therapeutics earned $2.32 in the first quarter, compared to $1.51 in the year-ago quarter. The current stock performance of CRISPR Therapeutics shows a 52-week-high of $169.76 and a 52-week-low of $42.51. Moreover, at the end of the last trading period, the closing price was at $64.64.

    BMO Capital initiated coverage on Centessa Pharmaceuticals PLC (NASDAQ:CNTA) with an Outperform rating. The price target for Centessa Pharmaceuticals is set to $19.00. In the first quarter, Centessa Pharmaceuticals showed an EPS of $0.60, compared to $4.97 from the year-ago quarter. The stock has a 52-week-high of $26.90 and a 52-week-low of $2.88. At the end of the last trading period, Centessa Pharmaceuticals closed at $4.14.

    BMO Capital initiated coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating. The price target for Precision BioSciences is set to $7.00. Precision BioSciences earned $0.46 in the first quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.38 and a 52-week-low of $1.11. Precision BioSciences closed at $1.15 at the end of the last trading period.

    With an Outperform rating, BMO Capital initiated coverage on Graphite Bio Inc (NASDAQ:GRPH). The price target seems to have been set at $12.00 for Graphite Bio. In the first quarter, Graphite Bio showed an EPS of $0.48, compared to $5.75 from the year-ago quarter. At the moment, the stock has a 52-week-high of $34.00 and a 52-week-low of $2.07. Graphite Bio closed at $2.14 at the end of the last trading period.

    With a Market Perform rating, BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM). The price target seems to have been set at $41.00 for Beam Therapeutics. Beam Therapeutics earned $1.01 in the first quarter, compared to $3.35 in the year-ago quarter. At the moment, the stock has a 52-week-high of $138.52 and a 52-week-low of $27.77. Beam Therapeutics closed at $32.23 at the end of the last trading period.

    BMO Capital initiated coverage on Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating. The price target for Intellia Therapeutics is set to $54.00. For the first quarter, Intellia Therapeutics had an EPS of $1.96, compared to year-ago quarter EPS of $0.69. At the moment, the stock has a 52-week-high of $202.73 and a 52-week-low of $37.08. Intellia Therapeutics closed at $41.44 at the end of the last trading period.

    Benchmark initiated coverage on Hub Group Inc (NASDAQ:HUBG) with a Buy rating. The price target for Hub Group is set to $90.00. Hub Group earned $2.58 in the first quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $87.20 and a 52-week-low of $60.81. At the end of the last trading period, Hub Group closed at $69.86.

    With a Buy rating, Benchmark initiated coverage on CC Neuberger Principal Holdings II (NYSE:PRPB). The price target seems to have been set at $12.00 for CC Neuberger Principal. The current stock performance of CC Neuberger Principal shows a 52-week-high of $9.99 and a 52-week-low of $9.75. Moreover, at the end of the last trading period, the closing price was at $9.95.

    Loop Capital initiated coverage on UnitedHealth Group Inc (NYSE:UNH) with a Buy rating. The price target for UnitedHealth Group is set to $575.00. UnitedHealth Group earned $5.49 in the first quarter, compared to $5.31 in the year-ago quarter. The stock has a 52-week-high of $553.29 and a 52-week-low of $383.12. At the end of the last trading period, UnitedHealth Group closed at $456.09.

    With a Buy rating, Loop Capital initiated coverage on CVS Health Corp (NYSE:CVS). The price target seems to have been set at $120.00 for CVS Health. For the first quarter, CVS Health had an EPS of $2.22, compared to year-ago quarter EPS of $2.04. The stock has a 52-week-high of $111.25 and a 52-week-low of $79.33. At the end of the last trading period, CVS Health closed at $89.85.

    With a Buy rating, Loop Capital initiated coverage on Tenet Healthcare Corp (NYSE:THC). The price target seems to have been set at $80.00 for Tenet Healthcare. For the first quarter, Tenet Healthcare had an EPS of $1.93, compared to year-ago quarter EPS of $1.30. At the moment, the stock has a 52-week-high of $92.65 and a 52-week-low of $50.37. Tenet Healthcare closed at $52.31 at the end of the last trading period.

    Loop Capital initiated coverage on Universal Health Services Inc (NYSE:UHS) with a Hold rating. The price target for Universal Health Services is set to $115.00. For the first quarter, Universal Health Services had an EPS of $2.15, compared to year-ago quarter EPS of $2.44. The stock has a 52-week-high of $165.00 and a 52-week-low of $99.53. At the end of the last trading period, Universal Health Services closed at $101.47.

    With a Hold rating, Loop Capital initiated coverage on Cigna Corp (NYSE:CI). The price target seems to have been set at $270.00 for Cigna. For the first quarter, Cigna had an EPS of $6.01, compared to year-ago quarter EPS of $4.73. At the moment, the stock has a 52-week-high of $273.57 and a 52-week-low of $191.74. Cigna closed at $248.30 at the end of the last trading period.

    Loop Capital initiated coverage on Molina Healthcare Inc (NYSE:MOH) with a Hold rating. The price target for Molina Healthcare is set to $310.00. Molina Healthcare earned $4.90 in the first quarter, compared to $4.44 in the year-ago quarter. The current stock performance of Molina Healthcare shows a 52-week-high of $350.19 and a 52-week-low of $239.30. Moreover, at the end of the last trading period, the closing price was at $254.73.

    With a Hold rating, Loop Capital initiated coverage on Community Health Systems Inc (NYSE:CYH). The price target seems to have been set at $5.00 for Community Health Systems. Community Health Systems earned $0.14 in the first quarter, compared to $0.36 in the year-ago quarter. The current stock performance of Community Health Systems shows a 52-week-high of $16.66 and a 52-week-low of $3.90. Moreover, at the end of the last trading period, the closing price was at $4.08.

    Loop Capital initiated coverage on Humana Inc (NYSE:HUM) with a Buy rating. The price target for Humana is set to $510.00. For the first quarter, Humana had an EPS of $8.04, compared to year-ago quarter EPS of $7.67. At the moment, the stock has a 52-week-high of $472.68 and a 52-week-low of $351.20. Humana closed at $423.21 at the end of the last trading period.

    Loop Capital initiated coverage on Centene Corp (NYSE:CNC) with a Buy rating. The price target for Centene is set to $100.00. In the first quarter, Centene showed an EPS of $1.83, compared to $1.63 from the year-ago quarter. The current stock performance of Centene shows a 52-week-high of $89.92 and a 52-week-low of $59.67. Moreover, at the end of the last trading period, the closing price was at $76.64.

    Piper Sandler initiated coverage on Broadmark Realty Capital Inc (NYSE:BRMK) with a Neutral rating. The price target for Broadmark Realty Capital is set to $7.00. For the first quarter, Broadmark Realty Capital had an EPS of $0.15, compared to year-ago quarter EPS of $0.18. The stock has a 52-week-high of $11.10 and a 52-week-low of $6.12. At the end of the last trading period, Broadmark Realty Capital closed at $6.20.

    JP Morgan initiated coverage on APi Group Corp (NYSE:APG) with a Neutral rating. The price target for APi Gr is set to $17.00. APi Gr earned $0.23 in the first quarter, compared to $0.12 in the year-ago quarter. The stock has a 52-week-high of $26.84 and a 52-week-low of $14.56. At the end of the last trading period, APi Gr closed at $14.69.

    JP Morgan initiated coverage on ZimVie Inc (NASDAQ:ZIMV) with a Neutral rating. The price target for ZimVie is set to $20.00. At the moment, the stock has a 52-week-high of $33.44 and a 52-week-low of $17.53. ZimVie closed at $18.08 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ACHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHC
    $AEO
    $APG
    $AXP

    CompanyDatePrice TargetRatingAnalyst
    Roblox Corporation
    $RBLX
    4/22/2026$140.00 → $125.00Buy
    Goldman
    UnitedHealth Group Incorporated
    $UNH
    4/22/2026$400.00Hold → Buy
    Argus
    Utz Brands Inc
    $UTZ
    4/20/2026$11.00 → $9.00Hold
    TD Cowen
    Westlake Corporation
    $WLK
    4/20/2026$120.00Buy → Hold
    Deutsche Bank
    AT&T Inc.
    $T
    4/16/2026$30.00Overweight
    Morgan Stanley
    Utz Brands Inc
    $UTZ
    4/14/2026$10.00Buy
    BTIG Research
    Centessa Pharmaceuticals plc
    $CNTA
    4/13/2026$38.00Buy → Hold
    Truist
    Toll Brothers Inc.
    $TOL
    4/13/2026$176.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $ACHC
    $AEO
    $APG
    $AXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    4/24/26 4:59:19 PM ET
    $CI
    Medical Specialities
    Health Care

    Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    4/24/26 4:58:52 PM ET
    $CI
    Medical Specialities
    Health Care

    Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    4/24/26 4:58:05 PM ET
    $CI
    Medical Specialities
    Health Care

    $ACHC
    $AEO
    $APG
    $AXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Grp. Pres., Global Comm. Serv. Joabar Raymond bought $4,054 worth of shares (23 units at $176.26) and sold $12,257 worth of shares (40 units at $306.42) (SEC Form 4)

    4 - AMERICAN EXPRESS CO (0000004962) (Issuer)

    3/13/26 4:40:36 PM ET
    $AXP
    Finance: Consumer Services
    Finance

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Mastantuono Gina bought $950 worth of shares (22 units at $43.20) and sold $790 worth of shares (22 units at $35.90) (SEC Form 4)

    4 - Roblox Corp (0001315098) (Issuer)

    2/13/26 5:07:32 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    $ACHC
    $AEO
    $APG
    $AXP
    SEC Filings

    View All

    SEC Form DEFA14A filed by Dream Finders Homes Inc.

    DEFA14A - Dream Finders Homes, Inc. (0001825088) (Filer)

    4/24/26 4:28:36 PM ET
    $DFH
    Homebuilding
    Consumer Discretionary

    SEC Form 10-Q filed by Meritage Homes Corporation

    10-Q - Meritage Homes CORP (0000833079) (Filer)

    4/24/26 4:20:05 PM ET
    $MTH
    Homebuilding
    Consumer Discretionary

    SEC Form S-8 filed by Dow Inc.

    S-8 - DOW INC. (0001751788) (Filer)

    4/24/26 4:15:32 PM ET
    $DOW
    Major Chemicals
    Industrials

    $ACHC
    $AEO
    $APG
    $AXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

    World's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Inv

    4/24/26 4:05:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Toll Brothers Announces Model Homes Opening at Alora in Orlando, Florida

    ORLANDO, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the highly anticipated model home grand opening at Alora, a luxury townhome community located in the vibrant Lake Nona area of Orlando, Florida. Home shoppers are invited to tour the stunning new model homes during the Grand Opening event on Saturday, April 25, from 11 a.m. to 3 p.m. at 9176 Sinatra Lane in Orlando. Alora features modern three-story townhomes with open-concept floor plans ranging up to 2,037 square feet, offering 2 to 4 bedrooms, 2 to 3 bathrooms, and 2-car garages. Flexible design options include a first-floor guest bedroom, home

    4/24/26 2:27:49 PM ET
    $TOL
    Homebuilding
    Consumer Discretionary

    The Cigna Group, Leading Health Plans Advance Work to Simplify Prior Authorization

    BLOOMFIELD, Conn., April 24, 2026 /PRNewswire/ -- The Cigna Group (NYSE:CI), a global health company, today joined leading health plans in a commitment to standardize electronic prior authorization submission requirements for commonly reviewed medical services, a step that will accelerate patients' access to care and simplify administrative work for providers and their teams. By the end of this year, the company expects that this standard approach will apply to medical services representing more than 70% of prior authorization volume, and additional services will be added on a r

    4/24/26 9:04:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $ACHC
    $AEO
    $APG
    $AXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman reiterated coverage on Roblox with a new price target

    Goldman reiterated coverage of Roblox with a rating of Buy and set a new price target of $125.00 from $140.00 previously

    4/22/26 8:06:58 AM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    UnitedHealth upgraded by Argus with a new price target

    Argus upgraded UnitedHealth from Hold to Buy and set a new price target of $400.00

    4/22/26 7:35:11 AM ET
    $UNH
    Medical Specialities
    Health Care

    TD Cowen reiterated coverage on Utz Brands with a new price target

    TD Cowen reiterated coverage of Utz Brands with a rating of Hold and set a new price target of $9.00 from $11.00 previously

    4/20/26 9:22:32 AM ET
    $UTZ
    Packaged Foods
    Consumer Staples

    $ACHC
    $AEO
    $APG
    $AXP
    Leadership Updates

    Live Leadership Updates

    View All

    Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

    World's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Inv

    4/24/26 4:05:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Acadia Healthcare Appoints David Duckworth as Interim Chief Financial Officer

    Reaffirms Financial Guidance for First Quarter and Full Year 2026 Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced the appointment of David Duckworth, former Chief Financial Officer of Acadia, as Interim Chief Financial Officer, effective May 1, 2026. Duckworth succeeds Todd Young, who is departing from the Company to pursue a CFO role at a private equity-backed animal health company. Young will remain with the Company through April 30, 2026, and will participate in the Company's first quarter earnings call scheduled for the morning of April 30. Debra K. Osteen, Chief Executive Officer of Acadia, said, "We are pleased to welcome David back as Int

    4/23/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    $AEO
    $APG
    $AXP
    Financials

    Live finance-specific insights

    View All

    HCA Healthcare Reports First Quarter 2026 Results

    HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2026. Key first quarter metrics (all percentage changes compare 1Q 2026 to 1Q 2025 unless otherwise noted): Revenues increased 4.3 percent to $19.109 billion Net income attributable to HCA Healthcare, Inc. increased 0.6 percent to $1.620 billion Diluted earnings per share and diluted earnings per share, as adjusted, increased 10.9 percent to $7.15 per diluted share Adjusted EBITDA increased 1.9 percent to $3.802 billion Cash flows from operating activities increased 22.0 percent to $2.014 billion Same facility admissions increased 0.9 percent and same fac

    4/24/26 7:00:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    American Express Reports First-Quarter 2026 Financial Results

    American Express Company (NYSE:AXP) today reported its first-quarter 2026 financial results. The earnings release and supplemental financial data are available on the company's Investor Relations website at http://ir.americanexpress.com. An investor conference call will be held at 8:30 a.m. (ET) today to discuss the company's first-quarter 2026 results. Live audio and presentation slides for the investor conference call will be available to the general public on the above-mentioned American Express Investor Relations website. A replay of the conference call will be available at the same website address following the call. ABOUT AMERICAN EXPRESS American Express (NYSE:AXP) is a global

    4/23/26 7:00:00 AM ET
    $AXP
    Finance: Consumer Services
    Finance

    Dow reports first quarter 2026 results

    MIDLAND, Mich., April 23, 2026 /PRNewswire/ -- Dow (NYSE:DOW): FINANCIAL HIGHLIGHTSNet sales were $9.8 billion, down 6% year-over-year, reflecting flat sales in Performance Materials & Coatings and declines in the other operating segments.Volume decreased 2% year-over-year, driven by declines in Industrial Intermediates & Infrastructure, which was impacted by the Middle East conflict. Gains in Packaging & Specialty Plastics from higher polyethylene volumes were more than offset by lower merchant olefins sales following the idling of a cracker in Europe, the Middle East, Africa a

    4/23/26 6:00:00 AM ET
    $DOW
    Major Chemicals
    Industrials

    $ACHC
    $AEO
    $APG
    $AXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Global

    SC 13G/A - Beam Global (0001398805) (Subject)

    12/6/24 4:12:03 PM ET
    $BEEM
    Semiconductors
    Technology

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care